MedTrace Logo

Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours

NCT06397963 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-26

No results posted yet for this study

Summary

This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).

Conditions

  • Solid Tumor, Adult

Interventions

BIOLOGICAL

GT307 injection

GT307 injection to treat solid tumours

Sponsors & Collaborators

  • The Affiliated Hospital of Xuzhou Medical University

    collaborator OTHER

  • Beijing GoBroad Hospital

    collaborator OTHER

  • Beijing Arion Cancer Center

    collaborator UNKNOWN

  • Grit Biotechnology

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-18
Primary Completion
2027-04-18
Completion
2027-04-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06397963 on ClinicalTrials.gov